Enzo Biochem Statistics
Share Statistics
Enzo Biochem has 52.4M
shares outstanding. The number of shares has increased by 1.84%
in one year.
| Shares Outstanding | 52.4M |
| Shares Change (YoY) | 1.84% |
| Shares Change (QoQ) | 0.3% |
| Owned by Institutions (%) | 26.26% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 7,843 |
| FTD / Avg. Volume | 2.26% |
Short Selling Information
The latest short interest is 364.9K, so 0.7% of the outstanding
shares have been sold short.
| Short Interest | 364.9K |
| Short % of Shares Out | 0.7% |
| Short % of Float | 0.78% |
| Short Ratio (days to cover) | 2 |
Valuation Ratios
The PE ratio is -2.23 and the forward
PE ratio is -4.48.
Enzo Biochem's PEG ratio is
0.04.
| PE Ratio | -2.23 |
| Forward PE | -4.48 |
| PS Ratio | 1.82 |
| Forward PS | 0.2 |
| PB Ratio | 1.03 |
| P/FCF Ratio | -2.16 |
| PEG Ratio | 0.04 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Enzo Biochem.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.82,
with a Debt / Equity ratio of 0.06.
| Current Ratio | 2.82 |
| Quick Ratio | 2.55 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | -0.42 |
| Debt / FCF | -0.13 |
| Interest Coverage | -49.83 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $255,256 |
| Profits Per Employee | $-208,624 |
| Employee Count | 125 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 2.53 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -70.48% in the
last 52 weeks. The beta is 1.16, so Enzo Biochem's
price volatility has been higher than the market average.
| Beta | 1.16 |
| 52-Week Price Change | -70.48% |
| 50-Day Moving Average | 0.44 |
| 200-Day Moving Average | 0.86 |
| Relative Strength Index (RSI) | 51.84 |
| Average Volume (20 Days) | 346,664 |
Income Statement
In the last 12 months, Enzo Biochem had revenue of 31.91M
and earned -26.08M
in profits. Earnings per share was -0.51.
| Revenue | 31.91M |
| Gross Profit | 14.63M |
| Operating Income | -9.82M |
| Net Income | -26.08M |
| EBITDA | -8.35M |
| EBIT | -9.62M |
| Earnings Per Share (EPS) | -0.51 |
Full Income StatementBalance Sheet
The company has 52.37M in cash and 3.51M in
debt, giving a net cash position of 48.86M.
| Cash & Cash Equivalents | 52.37M |
| Total Debt | 3.51M |
| Net Cash | 48.86M |
| Retained Earnings | -294.43M |
| Total Assets | 67.51M |
| Working Capital | 35.04M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -26.26M
and capital expenditures -545K, giving a free cash flow of -26.8M.
| Operating Cash Flow | -26.26M |
| Capital Expenditures | -545K |
| Free Cash Flow | -26.8M |
| FCF Per Share | -0.53 |
Full Cash Flow StatementMargins
Gross margin is 45.86%, with operating and profit margins of -30.77% and -81.73%.
| Gross Margin | 45.86% |
| Operating Margin | -30.77% |
| Pretax Margin | -30.77% |
| Profit Margin | -81.73% |
| EBITDA Margin | -26.16% |
| EBIT Margin | -30.77% |
| FCF Margin | -84.01% |
